Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Examining the Expanding Role of Patient Advocacy Groups

THE XTALKS BLOG

Patient Advocacy groups are playing a larger role in development of drugs to treat cancer and rare diseases.

Tweetables from this article:

Tweet: There are more than 7,000 known rare diseases, afflicting an estimated 30 million Americans http://ctt.ec/x3U52+There are more than 7,000 known rare diseases, afflicting an estimated 30 million Americans

Share this!

September 9, 2016 | by Megan Sims

Conventional wisdom holds that innovation follows need: that if enough people seek a new or better answer to a problem, enterprising companies will fill the void. While countless thousands of new and refined products bear this out, treatments for rare diseases are a persistently stubborn exception to the rule.

There are more than 7,000 known rare diseases, and these conditions afflict an estimated 30 million Americans (almost one in 10). Worldwide, some 350 million are living with a rare disease. But for 95 percent of these conditions, there are no FDA-approved treatments — not one.

In the entire decade that preceded enactment of the Food and Drug Administration’s Orphan Drug Act in 1983, the pharmaceutical industry introduced just 34 orphan drugs. These compounds are incredibly expensive to develop and most don’t get approved, making pharma companies understandably reticent to commit massive resources for the prospect of little reward.

But things are changing fast. The Orphan Drug Act and similar legislation in Europe, Asia, and Australia are stepping up incentives to address this large unmet need, creating a fertile environment to expand the strength and influence patient advocacy groups. These groups play an ever larger role in development of drugs to treat cancer and rare diseases, even directly funding clinical trials, recruiting patients, and contributing to study design.

Join Premier Research and rare disease advocacy pioneer Global Genes for a live webinar examining this important trend. Juliet Moritz, Executive Director of Rare Diseases at Premier Research, and Susan Stein, a member of the Global Genes board of directors, will present The Powerful and Evolving Role of Patient Advocacy Groups in Orphan Drug Development on Wednesday, September 14, at 11 a.m. Eastern time.

Register to attend this presentation, which will examine how advocacy organizations — once largely relegated to fundraising and lobbying roles — are greatly influencing orphan drug development from discovery to approval to market entry. These organizations are growing in sophistication, occupying more seats on the advisory boards and committees of prominent research groups and helping patients themselves become more involved in the design and execution of clinical trials.

The presenters will trace the expanding role of advocacy to 1988, when the FDA began working with HIV/AIDS patient advocates. They’ll discuss how the relationship between drug companies and patients is becoming a genuine partnership that will strengthen as regulatory and legislative changes — including the pending 21st Century Cures Act — further promote cooperation between patients and the organizations that champion their cause.



Keywords: Patient Advocacy, Premier Research, Rare Diseases  


| NEXT ARTICLE | MORE BLOG POSTS | NEWS | VIDEOS | POLLS & QUIZZES | WEBINARS |

 

        Share this with your colleagues!




        READ THESE NEXT
        The Future of Real-World Evidence

        March 14, 2017 - Life Sciences companies are performing advanced analytics, including cohort and predictive analytics, on top of these Real-World Evidence (RWE) data sources to understand the performance of their drugs and devices when used by actual, non-clinical trials patients.


        Pharmaceutical Industry Cannibalization: The Launch of Authorized Generics After the Loss of Market Exclusivity

        March 7, 2017 - Once a drug begins to reach the end of its patent period, it’s vulnerable to being scooped up by generic drugmakers who seek to develop a copycat version of the medication. Authorized generics are identical to the company’s branded product in terms of both active and inactive excipient ingredients; the only thing missing is the brand name and packaging that comes along with it.


        Five Ways to Optimize Capsule Filling Production

        March 2, 2017 - If your product’s ideal formulation is a capsule, there a few things you should consider before manufacturing.

        LEAVE A COMMENT
         
          
        THE XTALKS VITALS WEBINAR PRODUCTION TIPS BLOG

        Top Ten Webinar Production Tips of 2016

        REGISTER FOR THESE WEBINARS

        How to Improve the Speed and Efficiency of Your Clinical Trials


        High Performance Computing for High Content Screening - A Case Study


        The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


        Treatment of Psoriasis: Improvements Through Clinical Trials


        Copyright © 2016-2017 Honeycomb Worldwide Inc.